Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms. However, lack of standardized primers and PCR protocols has hampered comparability of data in previous clonality studies. To obtain reference values for Ig/TCR rearrangement patterns, 19 European laboratories investigated 188 T-cell malignancies belonging to five World Health Organization-defined entities. The TCR/Ig spectrum of each sample was analyzed in duplicate in two different laboratories using the standardized BIOMED-2 PCR multiplex tubes accompanied by international pathology panel review. TCR clonality was detected in 99% (143/145) of all definite cases of T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, peripheral T-cell lymphoma (unspecified) and angioimmunoblastic T-cell lymphoma (AILT), whereas nine of 43 anaplastic large cell lymphomas did not show clonal TCR rearrangements. Combined use of TCRB and TCRG genes revealed two or more clonal signals in 95% of all TCR clonal cases. Ig clonality was mostly restricted to AILT. Our study indicates that the BIOMED-2 multiplex PCR tubes provide a powerful strategy for clonality assessment in T-cell malignancies assisting the firm diagnosis of T-cell neoplasms. The detected TCR gene rearrangements can also be used as PCR targets for monitoring of minimal residual disease.
Introduction
Mature T-cell and natural killer cell neoplasms as defined by the World Health Organization (WHO) classification represent a heterogeneous group of lymphoid malignancies including predominantly nodal entities, extranodal lymphomas and T-cell leukemias. The classification of T-cell lymphomas has been based largely on morphological, immunohistochemical, clinical and for some subtypes also on genotypic criteria. [1] [2] [3] However, classification can be difficult as morphological and immunophenotypic features are not entirely disease-specific and can vary in given entities. 2, 4 In a proportion of cases, differentiation between non-neoplastic and neoplastic T cells remains difficult despite extensive immunostaining. Therefore, molecular clonality studies that can define the rearrangement profiles of the T-cell receptor (TCR) and immunoglobulin (Ig) genes are an important tool to confirm T-cell lymphoma diagnosis and to improve our understanding of T-lineage malignancies.
During T-cell ontogeny, TCR gene rearrangements play an important role. [5] [6] [7] [8] [9] The TCRD locus is the first to rearrange, starting with incomplete recombinations and progressing to Vd-(Dd-)Jd joinings. The TCRD variable region gene assembly does not appear to be ordered, as incomplete Vd-Dd, Dd-Dd and Dd-Jd rearrangements have all been described, 10 but recently these TCRD recombination events have been observed to occur in a hierarchical order at consecutive stages of thymic development. 11 The TCRG locus rearranges next, resulting in TCRgd expression, if the rearrangements are functional. TCRB gene rearrangements first join Db and Jb elements, followed by a second step of Vb segment recombination. 11 TCRA gene rearrangements occur during late T-cell development and functional TCRA rearrangements are followed by TCRab expression on the cell surface. 8, 9, 12 As the TCRD loci are located within the TCRA gene, all TCRab þ cells have their TCRD genes deleted on at least one allele, and approximately 80% of TCRab-lineage cells have biallelic TCRD deletions. 8, 9 Remarkably, virtually all TCRab þ T lymphocytes have rearranged TCRG genes and most TCRgd þ T cells have rearranged TCRB genes. 13 Generally, the TCR gene rearrangement patterns in T-cell lymphoid malignancies fit with the above described hierarchical order. 8, 14 Most mature T-cell lymphomas express TCRab, in the majority of cases combined with biallelic TCRD deletion, whereas a minority expresses TCRgd or do not express TCR molecules. 8, [15] [16] [17] [18] Polymerase chain reaction (PCR) techniques are increasingly used to detect clonal TCR gene rearrangements, but many existing PCR methods have limitations, even in the hands of reference laboratories, leading to considerable differences in published TCR/Ig rearrangement profiles for distinct types of T-cell malignancies. Therefore, the European BIOMED-2 Concerted Action BMH4-CT98-3936 developed standardized PCR protocols and PCR primers sets for clonality diagnostics. 19 In the present study, we used the BIOMED-2 panel of multiplex TCR and Ig PCR assays to investigate a large series of 188 T-cell malignancies, defined by the WHO classification. Specific goals of our study were (I) to further evaluate the informativity of the BIOMED-2 multiplex tubes for clonality testing and complementarity of the different TCR targets and (II) to define TCR and Ig rearrangement profiles for five welldefined and centrally reviewed T-cell malignancy categories: Tcell prolymphocytic leukemia (T-PLL), T-cell large granular lymphocytic leukemia (T-LGL), peripheral T-cell lymphoma unspecified (PTCL-U), angioimmunoblastic T-cell lymphoma (AILT) and anaplastic large cell lymphoma (ALCL).
Materials and methods

Patient samples
Two hundred and two freshly collected or frozen samples of five different entities of mature T-cell neoplasms, derived from seven national networks, were included into the analysis. Entities were defined according to the morphological and immunohistochemical criteria of the WHO classification. The recommended minimal marker panel for immunostaining is shown in Table 1 . In specific entities with peripheral blood involvement (T-PLL and T-LGL), diagnosis was confirmed through standard flow cytometric immunophenotyping. Samples were evaluated for their cytomorphology or histomorphology and for their immunophenotype by the local hematologists or pathologists and reviewed by national pathology review panels. All difficult cases, cases with discordant or atypical molecular results, and a random selection of classical cases were re-evaluated by the BIOMED-2 Pathology Review Panel (coordinator: JHJM van Krieken) with one or two expert hemato-pathologists being responsible for each diagnostic category (Supplementary Figure  1 , designated for website publication only). Samples were only selected, if sufficient frozen material was available to isolate at least 100 mg DNA using standard procedures. DNA quality was assessed using the BIOMED-2 control gene primer set. 19 
PCR amplification
This study was conducted in the frame of the BIOMED-2 Concerted Action BMH-CT98-3936. A total of 19 independent BIOMED-2 molecular diagnostic laboratories from seven European countries (The Netherlands, Belgium, Spain, Portugal, UK, Germany and France) participated in the molecular investigations of the mature T-cell malignancies with one to four participating laboratories per country. Data collection and coordination of the PCR-based clonality studies was performed by five disease category leaders (Supplementary Figure 1) .
PCR analyses of TCRB (Vb-Jb and Db-Jb), TCRG, TCRD, IGH (V H -J H and D H -J H ), IGK, IGL, BCL1-IGH and BCL2-IGH gene rearrangements were performed using the BIOMED-2 multiplex PCR tubes 19 that are now available from InVivoScribe Technologies, San Diego, CA (www.invivoscribe.com). To ensure the usage of identical primers in all participating laboratories, primers were centrally produced in bulk quantities by SigmaGenosys Ltd (Pampisford, UK), aliquoted in Rotterdam and distributed in standard packages to all participating centers.
NPM-ALK was amplified from DNA, as previously described by Waggott et al.
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Each patient sample was evaluated in two different laboratories in duplicate, using heteroduplex analysis and/or GeneScanning, implying that each sample was tested four times for all BIOMED-2 multiplex tubes. For heteroduplex analysis of the generated PCR products, unlabelled sets of primers were used. For GeneScanning, the oligonucleotides were 5 0 labeled with FAM. For analysis of all but 25 ALCL cases, the J primers of the TCRB and TCRG PCR assays were differentially labeled with FAM or HEX, which allowed further Jb and Jg differentiation. Adequate positive and negative controls were included in all experiments. In cases where PCR results were found to be discordant, a third laboratory repeated the duplicate PCR analyses.
Results and discussion
The aim of the study was to define reference values for PCR detectable TCR/Ig gene rearrangements in five strictly character- Including two cases initially characterized as PTCL-U.
PCR-based clonality assessment in T-cell malignancies
M Brüggemann et al ized entities of mature T-cell neoplasms using the systematic approach of the recently developed standardized BIOMED-2 PCR assays. The BIOMED-2 Pathology Review Panel that reevaluated all difficult cases, cases with discordant or atypical molecular results, and a random selection of classical cases, reclassified 18/202 investigated cases leading to exchange between the entities in four cases and exclusion from final evaluation in 14 cases. Accordingly, 188 cases (33 T-PLL, 28 T-LGL, 47 PTCL-U, 37 AILT and 43 ALCL) were retained for molecular analysis (Table 1) . PCR assessment of TCR/Ig as well as BCL1-IGH and BCL2-IGH gene rearrangements was performed in all cases and NPM-ALK1 PCR in the 43 histologically defined ALCL cases. No BCL1-IGH or BCL2-IGH rearrangements were detected in any of the samples. The Ig/TCR profiles of the five investigated entities are shown in Table 2 .
TCR/Ig gene rearrangement profiles per disease category
Out of 188 investigated cases, 177 (94%) exhibited clonal TCRB and/or TCRG gene rearrangements. Absence of clonal TCR gene rearrangements was restricted to 2/37 AILT cases (5%) and 9/43 ALCL (21%). T-large granular lymphocytic leukemia
T-prolymphocytic leukemia
All definite cases of T-LGL (28/28; 100%) showed clonal TCRB (27/28) and/or TCRG (27/28) signals. Three TCRB rearranged Table 2 Genotypic profiles in five categories of T-cell malignancies 
PCR-based
clonality assessment in T-cell malignancies M Brüggemann et al T-LGL leukemias exclusively demonstrated incomplete Db-Jb rearrangements
Angoimmunoblastic T-cell lymphoma
Of the 37 AILT cases studied, 25 (68%) exhibited exclusively clonal TCR rearrangements, 10 (27%) demonstrated both clonal TCR and Ig gene rearrangements and two (5%) showed clonal Ig gene rearrangements only (Figure 1 ). In 33 cases (89%) clonal TCRB joinings were detected, TCRG clonality was observed in 34 cases (92%) and 13 cases (35%) exhibited clonal TCRD gene rearrangements. In nine cases, three or four clonal TCRG signals were observed probably reflecting oligoclonality. In two of these nine cases, oligoclonal rearrangement patterns also concerned the TCRB locus. One-third of AILT cases (n ¼ 12) displayed one or more dominant Ig rearrangements. Seven cases (19%) contained clonal IGH V H -J H rearrangements, in six cases combined with other clonal Ig rearrangements. Remarkably, in five cases (14%) IGH D H -J H (n ¼ 4) or IGK (n ¼ 1) clonal rearrangements were the only detectable Ig gene rearrangements.
Anaplastic large cell lymphoma
Amongst the 43 ALCL cases, 34 showed a TCR þ /Ig À gene profile and nine were TCR À /Ig À (Figure 1 ). The NPM-ALK fusion was detected in 25/43 (58%) cases, of which all 22 tested were ALK1/p80 positive. A further nine cases (21%) expressed ALK1 protein but were NPM-ALK negative, and were considered to represent ALK variants. The TCR/Ig profiles of the 34 'Alkomas' are shown in Table 2 . None demonstrated an Ig rearrangement, eight were negative for clonal Ig and TCR rearrangements and as such most likely correspond to 'molecular null-ALCL'. The remaining 26 cases contained at least one clonal TCR rearrangement, with two of them showing more than two clonal TCRG signals, potentially reflecting oligoclonality. Nine cases (21%) were immunohistochemically ALK1 negative and were also NPM-ALK negative by DNA-based PCR. On case was negative for both Ig and TCR rearrangements and eight of these cases had undergone TCR rearrangement, with profiles similar to those found in ALK1-positive ALCL ( Table 2 ). Seven cases rearranged TCRB and TCRG with one of them showing more than two clonal TCRG signals. In one case TCR clonality was only demonstrated using the TCRG PCR assays.
In summary, all definite cases of T-PLL, T-LGL and PTCL-U showed TCRB and/or TCRG gene rearrangements which is in line with previously published data 9, 19, [21] [22] [23] [24] [25] and confirms the unprecedentedly high TCR clonality detection rate of the BIOMED-2 TCR multiplex system. In contrast, 24% of ALKpositive and 11% of ALK-negative ALCL did not show evidence of TCR clonality by our assays, and as such are likely to correspond to 'molecular null-ALCL'. 26 Also 5% of AILT cases lacked detectable TCR clonality which is compatible with other studies that showed absence of clonal TCR rearrangements in a small subset of AILT cases. [27] [28] [29] The majority of investigated T-cell lymphomas showed TCR rearrangement profiles analogous to mature TCRab þ postthymic T cells. 9, 30, 31 Between 58 and 71% of all TCRB gene rearrangements involved the Jb2 locus without significant differences in frequency distribution between the five investigated T-cell malignancies. The majority of TCRB rearranged cases showed Vb-Jb joinings on at least one allele. In each entity TCRG rearrangements most commonly used VgI-family segments that accounted for 54% (46-64%) of all clonal TCRG joinings. Additional 22% (14-32%) involved the Vg9 segment, almost exclusively in combination with Jg1.3/2.3 gene segments, whereas 22% (12-31%) used the Vg10 gene segment. Vg11 was rarely rearranged in the five investigated categories of T-cell malignancies. As expected, clonal TCRD rearrangements were detected only in a minority of cases (18%), as most TCRab þ T-cell malignancies have deleted both TCRD gene alleles. 8, 32, 33 Ig rearrangements occurred in 0-9% of T-PLL, T-LGL, PTCL-U and ALCL (Figure 1) . Clonal Ig signals were mostly weak and involved the IGH locus in the majority of cases. Whether these signals indicate clonal B-cell subpopulations that are also described in healthy individuals 34 or represent true crosslineage rearrangements in the malignant T cells cannot be definitely judged by this analysis alone, although cross-lineage Ig rearrangements would rather result in comparable strong clonal PCR products as generated by TCR PCR. Incidence of Ig clonality was highest in AILT (32%), close to the frequencies identified by Smith et al. 28 and Lome-Moldonado et al., 35 but higher than reported by Frizzera. 27 In this entity, Ig clonality most likely corresponds to expanded B-cell clones 28, [35] [36] [37] [38] in line with the occurrence of secondary Epstein-Barr viruspositive B-cell lymphoma after AILT. 38, 39 Also in T-LGL the association with B-cell proliferations is described. 34, 40 It should be noted that Ig clonality was also detected in a PCR-based clonality assessment in T-cell malignancies M Brüggemann et al subset of cases being reclassified after BIOMED-2 Pathology Panel Review (in three Ig clonal cases initially described as ALCL, a diffuse large B-cell lymphoma (DLBCL, n ¼ 1) or a Hodgkin's disease (n ¼ 2) could not be ruled out, and three Ig-positive cases described as PTCL-U were reclassified as AILT, hepatosplenic T-cell lymphoma and T-cell-rich DLBCL, respectively). Overall, this demonstrates that it is extremely important to interpret the PCR results within the whole diagnostic context.
Unusual TCR gene rearrangement profiles
In a subset of cases atypical clonal or solely polyclonal TCR rearrangements were observed: 24 cases demonstrated TCRG recombinations either without any detectable TCRB (n ¼ 6: one T-LGL, one PTCL-U, two AILT and two ALCL) or exclusively with incomplete TCRB joinings (n ¼ 18: two T-PLL, three T-LGL, six PTCL-U, six AILT, one ALCL). In addition, nine cases showed a TCRB þ /TCRG À rearrangement profile (two T-PLL, one T-LGL, three PTCL-U, one AILT, two ALCL), contrary to the expectation that TCRB recombinations are usually associated with TCRG gene rearrangements based on the presumed hierarchical order of TCRG rearranging before TCRB. 5, 8, 9, 41 The TCRB(Vb-Jb) À / TCRG þ profile may represent a TCRgd þ clone as confirmed in a subgroup of T-LGL patients by TCRab and TCRgd expression analysis, or a 'TCR silent T-cell lymphoma' 33 expressing neither TCRab nor TCRgd. However, this finding is difficult to prove because TCRab and TCRgd expression was not regularly assessed in our study. In part, TCR negativity might also be related to technical limitations of the PCR assays: TCRB (Vb-Jb) negativity might be caused by the inability of the BIOMED-2 Vbprimers to cover all non-functional Vb-segments. 14, 19, 22, 42 TCRG negativity may be related to the exclusion of the TCRG JgJ1.2 primer in the BIOMED-2 assays to reduce the risk of false positive results caused by misinterpretation of canonical Vg9-Jg1.2 rearrangements as clonal products. 43 However, Jg1.2 is rarely involved in T-cell neoplasms and is usually associated with a TCRG rearrangement on the other allele. 7, 19 Oligoclonality and pseudoclonality. In a subset of cases oligoclonal TCR gene rearrangement profiles were observed. However, the exact determination of oligoclonality is difficult to specify by PCR alone because the specific structure of the TCRB locus leads to the possibility of two rearrangements per allele, 22 allowing a maximum number of four TCRB rearrangements in a monoclonal T-cell population. In 20/188 cases (four T-LGL, nine AILT, four PTCL-U and three ALCL), the number of clonal TCRB and/or TCRG signals exceeded the maximum biallelic rearrangement numbers. In seven cases these atypical TCR profiles involved the TCRB locus (with no case showing more than five clonal TCRB signals), in 18 cases the TCRG PCR resulted in three to four dominant PCR products. These TCR rearrangement profiles may reflect true oligoclonality which occurs particularly in T-LGL 44 and AILT. 28, 29, 45 However, multiple clonal signals observed in cases at one locus only, may also be caused by pseudoclonal PCR products, particularly if the additive TCR signals concern the more rare and non-functional Vg10 or Vg11 rearrangements (n ¼ 7: one PTCL-U, three AILT and three ALCL), a potential pitfall that is also described by Langerak et al. 46 who analyzed a large series of well-defined reactive lesions.
Strategical implications for clonality analysis
In our study, 168/188 investigated T-cell malignancies (89%) exhibited clonal TCRG gene rearrangements, which are most commonly used as PCR targets for clonality studies in T-cell malignancies, as almost all T-cell malignancies have clonal TCRG gene rearrangements irrespective of TCRab and TCRgd lineage and because the restricted TCRG germline repertoire facilitates the design of PCR assays. 9, 17, [47] [48] [49] [50] In this report, the addition of TCRB rearrangements as PCR targets enhanced the clonality detection rate to 94% as our TCRB and TCRG assays yielded complementary results in a significant proportion of cases. Nine cases without a detectable TCRG gene rearrangement demonstrated one or several clonal TCRB joinings, whereas six cases without evidence of a TCRB gene rearrangement had undergone at least one TCRG joining. In addition, the combined use of both targets for clonality assessment led to a PCR-based clonality assessment in T-cell malignancies M Brüggemann et al significant increase in the number of clonal rearrangements detected per sample, resulting in 2 or even X3 independent clonal signals in 169/188 (90%) and 134/188 (71%) cases, respectively (Table 3) . Particularly the implementation of incomplete Db-Jb rearrangements as additional PCR targets enhanced the number of clonal signals per sample as clonal DbJb joinings were detected in 110/188 (59%) investigated T-cell malignancies. Therefore, using the five BIOMED-2 TCRB/TCRG PCR multiplex tubes in parallel has the advantage of frequently obtaining multiple positive signals, thereby confirming clonality results and supporting the diagnostic process. As expected, TCRD PCR provided extra positive results only in a minority of cases and might therefore not routinely be applied for clonality diagnostics in mature T-cell lymphoma. However, it is a useful PCR target in immature T-cell malignancies and in mature T-cell malignancies of the gd-lineage. The here presented molecular clonality studies were restricted to fresh or frozen samples. However, the BIOMED-2 protocols also work well with DNA extracted from paraffin-embedded material provided that the quality of the DNA allows the amplification of PCR products of 300 bp or more. 19, 51 Consequently DNA from paraffin-embedded tissues should always be tested for quality. 19 
Conclusion
This large European network study shows that the combined use of the BIOMED-2 multiplex PCR tubes is a powerful strategy for clonality diagnostics in T-cell malignancies as it allows standardized and reproducible clonality assessment resulting in unprecedentedly high clonality detection rates. However, it is extremely important to have an understanding of the nature of Ig and TCR gene rearrangements before these loci are used as PCR targets in clonality diagnostics. 19 In addition, PCR results in lymphoma should be interpreted within their clinical context, as classification of T-cell neoplasms is a multiparameter approach, integrating clinical, morphological, immunophenotypical and genetic data. Finally, the detected clonal TCR gene rearrangements can not only be used for supporting the diagnosis, but they can also be used as PCR targets for detection of minimal residual disease to monitor treatment effectiveness.
